Ex vivo culture of lesional psoriasis skin for pharmacological testing

dc.contributor.authorTiirikainen, Minna Lund
dc.contributor.authorWoetmann, Anders
dc.contributor.authorNorsgaard, Hanne
dc.contributor.authorSantamaria Babí, Luis F.
dc.contributor.authorLovato, Paola
dc.date.accessioned2020-10-13T14:23:03Z
dc.date.available2020-10-13T14:23:03Z
dc.date.issued2019-12-27
dc.date.updated2020-10-13T14:23:03Z
dc.description.abstractBackground: Psoriasis is a chronic, inflammatory skin disorder resulting from a complex interplay between immune and skin cells via release of soluble mediators. While a lot is known about the molecular mechanisms behind psoriasis pathogenesis, there is still a need for preclinical research models that accuratelyreplicate the disease. Objective: This study aimed to develop and characterize ex vivo culture of psoriasis skin as a model for pharmacological testing, where the immunological events of psoriasis can be followed. Methods: Full thickness punch biopsies of lesional psoriasis skin were cultured in submerged conditions up to 144 h followingin situ T cell stimulation with rhIL-23 and anti-CD3 and anti-CD28 antibodies. The Tcell mediated skin inflammation was assessed by gene and protein l analysis for a panel of inflammatory mediators. Tissue integrity and morphology were evaluated by histological analysis. Results: T cell stimulation resulted in functional and psoriasis specificin situ activation of T cells. The expression levels of most of the proinflammatory mediators related to both immune and skin cells were comparable to these in freshly isolated tissue at 48 and 96 h of culture. Tissue integrity and morphology were sustained up to 96 h. Treatment with a corticosteroid reduced the expression of several proinflammatory cytokines and chemokines, whereas anti-IL-17A antibody treatment reduced the expression of the IL-17A downstream markers IL-8 and DEFB4. Conclusion: By preserving keyimmunopathological mechanisms of psoriasis, ex vivo culture of psoriasis skin can be used for the investigation of inflammatory processes of psoriasis and for preclinical drug discovery research.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec695091
dc.identifier.issn0923-1811
dc.identifier.pmid31948839
dc.identifier.urihttps://hdl.handle.net/2445/171181
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.jdermsci.2019.12.010
dc.relation.ispartofJournal of Dermatological Science, 2019, vol. 97, num. 2, p. 109-116
dc.relation.urihttps://doi.org/10.1016/j.jdermsci.2019.12.010
dc.rightscc-by-nc-nd (c) Tiirikainen et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
dc.subject.classificationPsoriasi
dc.subject.classificationImmunoregulació
dc.subject.otherPsoriasis
dc.subject.otherImmunoregulation
dc.titleEx vivo culture of lesional psoriasis skin for pharmacological testing
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
695091.pdf
Mida:
2.59 MB
Format:
Adobe Portable Document Format